Susceptibility to various antimicrobial agents ofStaphylococcus aureus isolates from cystic fibrosis patients

Ballestero, S; Villaverde, Roberto; Escobar, Héctor; Baquero, Fernando

doi:10.1007/bf01961145

Cited by 7 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study was a pharmacokinetic study of linezolid (Keel 2011) and another study was of a new formulation of tobramycin (Keller 2010). Finally, non-randomised studies were excluded (Ballestero 1992;Brown 1980;Denning 1977;Feigelson 1993;Jensen 1990;Kerrebijn 1984;Sza 1982;Wright 1970).…”

Section: Excluded Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

Smyth

Rosenfeld

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Section: Excluded Studiesmentioning

confidence: 99%

“…Low risk Allocation was given by telephone from the co-ordinating centre and concealed from the local investigator until the participant was enrolled. Ballestero 1992 Non-randomised.…”

Section: Smyth 2014mentioning

confidence: 99%

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

Smyth

Rosenfeld

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Although pseudomonal species are the predominant bacteria in the respiratory tracts of CF patients, Staphylococcus aureus may be present. In CF patients, S. aureus strains cultured from the respiratory tract are usually susceptible to methicillin, with a reported incidence of methicillin resistance of approximately 3% (1,3). Treatment of methicillin-susceptible staphylococcal infections in CF patients has been traditionally accomplished with beta-lactams such as nafcillin or cephalosporins.…”

mentioning

confidence: 99%

Pharmacokinetics of vancomycin in adult cystic fibrosis patients

Pleasants

Michalets

Williams

et al. 1996

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Although the depositions of many antibiotics are altered in cystic fibrosis patients, that of vancomycin has not been studied. To assess vancomycin pharmacokinetics, 10 adult cystic fibrosis patients were given a parenteral dose of vancomycin (15 mg/kg) during the first 72 h of hospitalization for acute bronchopulmonary exacerbation. Blood samples were obtained at 0, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 15, and 24 h. The mean (standard deviation) weight, measured creatinine clearance, and Taussig clinical score were 51 (13) kg, 130 (39) ml/min/1.73 m2, and 64 (13), respectively. Multicompartmental pharmacokinetic parameters were best described by a two-compartment model. The mean (standard deviation) volume of distribution, total body clearance, and terminal elimination rate constant were 0.58 (0.15) liter/kg, 91 (19) ml/min/1.73 m2, and 0.123 (0.05) h-1, respectively. These values were consistent with vancomycin pharmacokinetic parameters obtained in previous studies of healthy adult volunteers. Vancomycin dosages predicted by using a two-compartment Bayesian model were approximately 15 mg/kg every 8 to 12 h. There were poor correlations between clinical score or creatinine clearance and any pharmacokinetic parameter (r values of < 0.32). The coefficient of correlation between urine flow rate and total body clearance was 0.7 (P < 0.05). Adult cystic fibrosis patients exhibit a disposition of vancomycin similar to that exhibited by healthy adults, and thus cystic fibrosis does not alter vancomycin pharmacokinetics.

show abstract

Section: Excluded Studiesmentioning

confidence: 99%

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

Rosenfeld

Rayner²,

Smyth

2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Staphylococcus aureus causes pulmonary infection in young children with cystic fibrosis. Prophylactic antibiotics are prescribed hoping to prevent such infection and lung damage. Antibiotics have adverse effects and long-term use might lead to infection with Pseudomonas aeruginosa. Objectives To assess continuous oral antibiotic prophylaxis to prevent the acquisition of Staphylococcus aureus versus no prophylaxis in people with cystic fibrosis, we tested these hypotheses. Prophylaxis: 1. improves clinical status, lung function and survival; 2. causes adverse effects (e.g. diarrhoea, skin rash, candidiasis); 3. leads to fewer isolates of common pathogens from respiratory secretions; 4. leads to the emergence of antibiotic resistance and colonisation of the respiratory tract with Pseudomonas aeruginosa. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Companies manufacturing anti-staphylococcal antibiotics were contacted.

show abstract

Susceptibility to various antimicrobial agents ofStaphylococcus aureus isolates from cystic fibrosis patients

Cited by 7 publications

References 3 publications

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

Pharmacokinetics of vancomycin in adult cystic fibrosis patients

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

Contact Info

Product

Resources

About